Drug Type Monoclonal antibody |
Synonyms S-95029, S095029, SYM025 + [1] |
Target |
Action inhibitors, antagonists |
Mechanism HLA-E inhibitors(major histocompatibility complex, class I, E inhibitors), NKG2A antagonists(killer cell lectin like receptor C1 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Gastrooesophageal junction cancer | Phase 2 | United States | 13 Aug 2024 | |
Gastrooesophageal junction cancer | Phase 2 | China | 13 Aug 2024 | |
Gastrooesophageal junction cancer | Phase 2 | Japan | 13 Aug 2024 | |
Gastrooesophageal junction cancer | Phase 2 | Australia | 13 Aug 2024 | |
Gastrooesophageal junction cancer | Phase 2 | Austria | 13 Aug 2024 | |
Gastrooesophageal junction cancer | Phase 2 | Belgium | 13 Aug 2024 | |
Gastrooesophageal junction cancer | Phase 2 | Brazil | 13 Aug 2024 | |
Gastrooesophageal junction cancer | Phase 2 | Canada | 13 Aug 2024 | |
Gastrooesophageal junction cancer | Phase 2 | Denmark | 13 Aug 2024 | |
Gastrooesophageal junction cancer | Phase 2 | France | 13 Aug 2024 |
NCT05162755 (SITC2024) Manual | Phase 1 | 41 | S095029 monotherapy | qyduwljowj(bevjpayaee) = lidxhdkvxs vykrtjteji (ejpgkwqxjj ) View more | Positive | 05 Nov 2024 | |
qyduwljowj(bevjpayaee) = adjfxtwges vykrtjteji (ejpgkwqxjj ) |